GlassScriptPhysician profile
George B Sonnier
NPI 1861495046
$8,968.26
in general payments reported to CMS, 2019-2025
32 companies · $573 in 2025
The $573 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $999 · 2021: $1,279 · 2022: $1,585 · 2023: $1,767 · 2024: $1,436 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,661 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.23 |
| Education | $114.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,530.45 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,084.98 | 2019-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $839.22 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $728.64 | 2019-2025 | |
| Janssen Biotech, INC. | $700.58 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $577.77 | 2019-2024 | Libtayo, Dupixent |
| Genzyme Corporation | $402.80 | 2019-2025 | |
| Stemline Therapeutics INC. | $265.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $257.68 | 2023-2024 | Sotyktu |
| Amgen INC. | $207.30 | 2019-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $191.31 | 2019-2025 | Odomzo, Blu-U |
| Janssen Scientific Affairs, LLC | $174.62 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.72 | 2023-2025 | Spevigo |
| Krystal Biotech INC | $130.74 | 2023 | Vyjuvek |
| Leo Pharma INC. | $124.74 | 2019-2025 | Adbry, Anzupgo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $94.59 | 2019-2020 | |
| Pfizer INC. | $74.00 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.44 | 2019 | |
| Biofrontera INC. | $53.82 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $52.36 | 2024-2025 | Zoryve |
| Incyte Corporation | $43.41 | 2022 | |
| Celgene Corporation | $38.94 | 2019 | |
| Springworks Therapeutics, INC. | $27.51 | 2025 | Gomekli |
| Organogenesis INC. | $22.36 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $20.45 | 2019 | |
| Sebela Pharmaceuticals INC. | $19.51 | 2019 | |
| Genentech USA, INC. | $17.48 | 2021 | |
| Dermira, INC. | $16.95 | 2020 | |
| Epi Health, LLC | $15.13 | 2019 | |
| Nabriva Therapeutics, Plc | $14.44 | 2022 | |
| Almirall LLC | $14.14 | 2021 | |
| Kyowa Kirin, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sonnier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.